5-甲基-1,2,4-噁二唑-3-羰酰氯 | 155062-48-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-甲基-1,2,4-噁二唑-3-羰酰氯
• 英文名称: 5-methyl-1,2,4-oxadiazole-3-carbonyl chloride
• CAS: 155062-48-9
• 化学式: C₄H₃ClN₂O₂
• 分子量: 146.533
• InChiKey: JSJLXRLKTNXIBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  56
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-甲基-1,2,4-噁二唑-3-羰酰氯 、 二甲羟胺盐酸盐 在 potassium carbonate 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 N-methoxy-N-methyl-5-methyl-1,2,4-oxadiazole-3-carboxamide
  参考文献：
  名称：

  生长抑素受体拮抗剂的路线开发和多千克GMP传递

  摘要：

  描述了MK-4256首次GMP交付的多公斤级路线开发和演示。聚合路线的关键方面包括区域选择性绿色碘化，一锅法合成恶二唑，有效的酮Pictet-Spengler反应以及通过结晶的非对映异构体升级，从而提供6 kg的API。回收程序可以从Pictet-Spengler反应中，从富含不需要的非对映异构体的非对映异构体混合物中增加所需非对映异构体的收率。

  DOI：

  10.1021/op300128c
• 作为产物：
  描述：

  5-甲基-1,2,4-噁二唑-3-羧酸钾 在 草酰氯 作用下， 以 二氯甲烷 为溶剂， 生成 5-甲基-1,2,4-噁二唑-3-羰酰氯
  参考文献：
  名称：

  生长抑素受体拮抗剂的路线开发和多千克GMP传递

  摘要：

  描述了MK-4256首次GMP交付的多公斤级路线开发和演示。聚合路线的关键方面包括区域选择性绿色碘化，一锅法合成恶二唑，有效的酮Pictet-Spengler反应以及通过结晶的非对映异构体升级，从而提供6 kg的API。回收程序可以从Pictet-Spengler反应中，从富含不需要的非对映异构体的非对映异构体混合物中增加所需非对映异构体的收率。

  DOI：

  10.1021/op300128c

文献信息

• Route Development and Multikilogram GMP Delivery of a Somatostatin Receptor Antagonist
  作者：Rebecca T. Ruck、Mark A. Huffman、Gavin W. Stewart、Ed Cleator、Wynne V. Kandur、Mary M. Kim、Dalian Zhao

  DOI：10.1021/op300128c

  日期：2012.8.17

  Route development and demonstration on multikilogram scale for the first GMP delivery of MK-4256 are described. Key aspects of the convergent route include a regioselective green iodination, one-pot oxadiazole synthesis, and an efficient ketone Pictet–Spengler reaction with diastereomeric upgrade via crystallization to afford 6 kg of API. A recycle procedure augmented the yield of desired diastereomer

  描述了MK-4256首次GMP交付的多公斤级路线开发和演示。聚合路线的关键方面包括区域选择性绿色碘化，一锅法合成恶二唑，有效的酮Pictet-Spengler反应以及通过结晶的非对映异构体升级，从而提供6 kg的API。回收程序可以从Pictet-Spengler反应中，从富含不需要的非对映异构体的非对映异构体混合物中增加所需非对映异构体的收率。
• Substituted sulphonyl amino(thio)carbonyl compounds and their use as herbicides
  申请人：Bayer Aktiengesellschaft

  公开号：US06677277B1

  公开（公告）日：2004-01-13

  The invention relates to novel sulfonylamino(thio)carbonyl compounds of the formula (I), in which n represents the numbers 0, 1 or 2, A represents a single bond, or oxygen or sulfur, or the grouping N—R, in which R represents hydrogen, alkyl, alkenyl, alkinyl or cycloalkyl, Q represents oxygen or sulfur, R1 represents hydrogen or formyl, or represents respectively optionally substituted alkyl, alkoxy, alkylamino, alkoxyamino, dialkylamino, N-alkoxy-N-alkyl-amino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, alkenyl, alkinyl, cycloalkyl, cycloalkylcarbonyl or cycloalkylsulfonyl, R2 represents cyano or halogen, or represents respectively optionally substituted alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, dialkylaminosulfonyl, alkenyl, alkinyl, alkenyloxy or alkinyloxy, and R3 represents respectively optionally substituted heterocyclyl having 5 ring members of which at least one is oxygen, sulfur or nitrogen and from one to three further ring members can be nitrogen, and salts of compounds of the formula (I), a plurality of processes and novel intermediates for preparing them and their use as herbicides.

  该发明涉及一种新型的磺酰胺基(硫)羰基化合物，其化学式为(I)，其中n代表数字0、1或2，A代表单键，或氧或硫，或基团N—R，其中R代表氢、烷基、烯基、炔基或环烷基，Q代表氧或硫，R1代表氢或甲酰基，或分别代表可选择取代的烷基、烷氧基、烷基氨基、烷氧基氨基、二烷基氨基、N-烷氧基-N-烷基-氨基、烷基羰基、烷氧羰基、烷基磺酰基、烯基、炔基、环烷基、环烷基羰基或环烷基磺酰基，R2代表氰基或卤素，或分别代表可选择取代的烷基、烷氧基、烷硫基、烷磺酰基、二烷基氨基磺酰基、烯基、炔基、烯基氧基或炔基氧基，R3代表分别可选择取代的含有5个环成员的杂环烷基，其中至少有一个是氧、硫或氮，另外一到三个环成员可以是氮，并且化合物的盐具有化学式(I)，多种制备它们的方法和新的中间体以及它们作为除草剂的用途。
• The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes
  作者：Shuwen He、Zhixiong Ye、Quang Truong、Shrenik Shah、Wu Du、Liangqin Guo、Peter H. Dobbelaar、Zhong Lai、Jian Liu、Tianying Jian、Hongbo Qi、Raman K. Bakshi、Qingmei Hong、James Dellureficio、Alexander Pasternak、Zhe Feng、Reynalda deJesus、Lihu Yang、Mikhail Reibarkh、Scott A. Bradley、Mark A. Holmes、Richard G. Ball、Rebecca T. Ruck、Mark A. Huffman、Frederick Wong、Koppara Samuel、Vijay B. Reddy、Stan Mitelman、Sharon X. Tong、Gary G. Chicchi、Kwei-Lan Tsao、Dorina Trusca、Margaret Wu、Qing Shao、Maria E. Trujillo、George J. Eiermann、Cai Li、Bei B. Zhang、Andrew D. Howard、Yun-Ping Zhou、Ravi P. Nargund、William K. Hagmann

  DOI：10.1021/ml300063m

  日期：2012.6.14

  A structure-activity relationship study of the imidazolyl-beta-tetrahydrocarboline series identified MK-4256 as a potent, selective SSTR3 antagonist, which demonstrated superior efficacy in a mouse oGTT model. MK-4256 reduced glucose excursion in a dose-dependent fashion with maximal efficacy achieved at doses as low as 0.03 mg/kg po. As compared with glipizide, MK-4256 showed a minimal hypoglycemia risk in mice.
• Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes
  作者：Shrenik K. Shah、Shuwen He、Liangqin Guo、Quang Truong、Hongbo Qi、Wu Du、Zhong Lai、Jian Liu、Tianying Jian、Qingmei Hong、Peter Dobbelaar、Zhixiong Ye、Edward Sherer、Zhe Feng、Yang Yu、Frederick Wong、Koppara Samuel、Maria Madiera、Bindhu V. Karanam、Vijay B. Reddy、Stan Mitelman、Sharon X. Tong、Gary G. Chicchi、Kwei-Lan Tsao、Dorina Trusca、Yue Feng、Margaret Wu、Qing Shao、Maria E. Trujillo、George J. Eiermann、Cai Li、Michele Pachanski、Guillermo Fernandez、Donald Nelson、Patricia Bunting、Pierre Morissette、Sylvia Volksdorf、Janet Kerr、Bei B. Zhang、Andrew D. Howard、Yun-Ping Zhou、Alexander Pasternak、Ravi P. Nargund、William K. Hagmann

  DOI：10.1021/ml500514w

  日期：2015.5.14

  The imidazolyl-tetrahydro-beta-carboline class of sstr3 antagonists have demonstrated efficacy in a murine model of glucose excursion and may have potential as a treatment for type 2 diabetes. The first candidate in this class caused unacceptable QTc interval prolongation in oral, telemetrized cardiovascular (CV) dogs. Herein, we describe our efforts to identify an acceptable candidate without CV effects. These efforts resulted in the identification of (1R,3R)-3-(4-(5-fluoropyridin-2-yl)-1H-imidazol-2-yl)-1-(1-ethyl-pyrazol-4-yl)-1-(3-methyl-1,3,4-oxadiazol-3H-2-one-5-yl)-2,3,4,9-tetrahydro-1H-beta-carboline (17e, MK-1421).